Pharmaceutical Stocks Worth Watching – July 29th

01 Aug 2025, 10:24 by Doug Wharley · The Cerbat Gem

Novo Nordisk A/S, Eli Lilly and Company, Merck & Co., Inc., Sarepta Therapeutics, and AstraZeneca are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and market drugs and medical therapies. Investors in these stocks gain exposure to the biotechnology and healthcare sectors, where returns can be driven by drug approvals, clinical trial results, and regulatory changes. Since product pipelines and patent lifecycles heavily influence performance, pharmaceutical stocks can be subject to higher volatility compared with more diversified industries. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Shares of Novo Nordisk A/S stock traded down $14.74 during trading on Tuesday, reaching $54.27. 92,260,364 shares of the stock traded hands, compared to its average volume of 9,761,952. The company has a market capitalization of $242.29 billion, a price-to-earnings ratio of 16.05, a P/E/G ratio of 1.38 and a beta of 0.64. The business has a fifty day simple moving average of $70.71 and a two-hundred day simple moving average of $73.51. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a 52-week low of $53.51 and a 52-week high of $139.74.

Read Our Latest Research Report on NVO

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of Eli Lilly and Company stock traded down $35.28 during trading on Tuesday, reaching $772.83. 4,628,742 shares of the stock traded hands, compared to its average volume of 3,765,249. The company has a market capitalization of $732.44 billion, a price-to-earnings ratio of 62.88, a P/E/G ratio of 1.18 and a beta of 0.40. The business has a fifty day simple moving average of $773.01 and a two-hundred day simple moving average of $800.67. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Read Our Latest Research Report on LLY

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of NYSE:MRK traded down $1.93 during trading on Tuesday, reaching $82.13. The company’s stock had a trading volume of 19,730,982 shares, compared to its average volume of 15,846,243. The company has a current ratio of 1.41, a quick ratio of 1.16 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $123.94. The firm’s 50 day simple moving average is $80.17 and its two-hundred day simple moving average is $84.99. The stock has a market capitalization of $206.23 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.39.

Read Our Latest Research Report on MRK

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Shares of NASDAQ:SRPT traded up $2.55 during trading on Tuesday, reaching $16.41. The company’s stock had a trading volume of 56,744,814 shares, compared to its average volume of 5,372,236. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $146.38. The firm’s 50 day simple moving average is $25.64 and its two-hundred day simple moving average is $62.85. The stock has a market capitalization of $1.61 billion, a PE ratio of -6.10 and a beta of 0.45.

Read Our Latest Research Report on SRPT

AstraZeneca (AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

NASDAQ AZN traded up $2.30 during trading on Tuesday, hitting $74.13. The stock had a trading volume of 11,295,021 shares, compared to its average volume of 5,313,532. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. The stock has a market capitalization of $229.90 billion, a price-to-earnings ratio of 29.80, a P/E/G ratio of 1.34 and a beta of 0.37. AstraZeneca has a one year low of $61.24 and a one year high of $87.68. The stock has a 50 day simple moving average of $71.20 and a 200 day simple moving average of $71.20.